Keywords
pibrentasvir,Mavyret,abt-530,hepatitis c treatment,direct-acting antiviral,ns5a inhibitor,c57h65f5n10o8,molecular formula,c57h65f5n10o8,structural formula,chemical structure,carboxylic acid,amide bond,oxadiazole ring,imidazole ring,pyrrolidine ring,methoxy group,methyl group,ns5a inhibitor,antiviral,virus inhibition,virus replication,direct-acting antiviral mechanism,viral protein inhibition,hcv lifecycle interference,rna virus targeting,glecaprevir,treatment,therapy,therapeutics,carbon,hydrogen,nitrogen,oxygen,fluorine,single bonds,double bonds,aromatic bonds,antiviral pharmacology,hepatitis c treatment,direct-acting antivirals,ns5a inhibitors,pharmaceutical chemistry,drug design,therapeutics,pharmacodynamics,pharmacokinetics,combination therapy,ns5a protein,hepatitis c virus,viral protein,hcv genotype targeting,direct-acting antiviral agents,chronic hepatitis c,pibrentasvir pharmacology,drug metabolism,structural,formula,chemical compound,structural chemistry,bond,line bond,charge,proj-creative-abx-24q2,proj-creative-abx-24q2-novartis,pibrentasvir